LFCR NASDAQ
Lifecore Biomedical, Inc.
1W: +55.7%
1M: +38.0%
3M: +29.5%
YTD: -15.5%
1Y: -8.8%
3Y: -13.7%
5Y: -36.0%
$6.54
+0.01 (+0.15%)
Weekly Expected Move ±28.2%
$3
$5
$7
$8
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.45
Bullish
3 bullish
0 neutral
1 bearish
Articles (7d)
4
Daily Sentiment (7 Days)
Articles (47)
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Stock Has Average Price Target of $6.50
Lifecore agrees to acquisition with CVRs up to $160 million
Lifecore Biomedical to be acquired by Webster Equity Partners
Lifecore Biomedical to be Acquired by Webster Equity Partners
BlackRock Inc. Acquires New Stake in Lifecore Biomedical, Inc. $LFCR
Lifecore Biomedical rises on deal with global pharma company
Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update
Can Lifecore Biomedical, Inc. (LFCR) Unlock Long-Term Value Through Expanding Biopharma Collaborations?
Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company
Lifecore reaffirms 2026 guidance of $120M-$125M revenue and $20.5M-$25M adjusted EBITDA while targeting 12% revenue CAGR by 2029
Earnings Scheduled For May 6, 2026
Lifecore Biomedical GAAP EPS of $0.43 beats by $0.72, revenue of $23.2M misses by $2.76M
Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update
Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update
Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Receives Average Recommendation of “Hold” from Analysts
Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
Catalyst Watch: Eyes on post-Iran economic data, Fedspeak, and cybersecurity
Lifecore Stock Sinks As Delayed Launches Push Growth Further Out
Lifecore targets 12% revenue CAGR through 2029 as midterm pipeline milestones shift
12 Health Care Stocks Moving In Monday's Intraday Session
Lifecore Biomedical GAAP EPS of -$0.16, revenue of $35.75M
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update
Earnings Scheduled For March 16, 2026
Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag
Lifecore Biomedical (NASDAQ:LFCR) Stock Price Down 2.9% – Here’s Why
Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment
Lifecore Biomedical to Participate at DCAT Week 2026
Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Settles
HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Settles
Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Reaches Settlement
Lifecore Biomedical: The Turnaround Is Just Getting Started
Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Reaches Settlement
HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Lifecore Biomedical to be Added to Nasdaq Biotech Index
Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer
Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference
Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights